Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment (ROSY-F)

AstraZeneca

Status and phase

Enrolling

Phase 3

Conditions

Asthma

Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Hypereosinophilic Syndrome (HES)

Treatments

Drug: Benralizumab

Study type

Interventional

Funder types

Industry

Identifiers

NCT07444567

D3250N00036

Details and patient eligibility

About

The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as judged by the Investigator, while monitoring long-term safety and tolerability of benralizumab.

Full description

This will be an open-label, non-randomised, multicentre, international study for eligible participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment as judged by the Investigator. Any clinical study conducted with benralizumab (Fasenra) for indications such as asthma, EGPA, HES and future indications from additional parent studies, is potentially a parent study.

Each participant continuing to receive clinical benefit from benralizumab but with no access to the drug after exiting the parent study must be seen at the Investigator site, offered the opportunity to transition to the ROSY-F. The duration of clinical benefit from study treatment for an individual participant can exceed the duration of a clinical trial. To ensure continued supply of treatment to a participant who, as judged by the Investigator, is still receiving benefit when he/she either completes or exits the parent study or when the parent study closes, a roll-over study is the most universally acceptable mechanism for continuing to provide ongoing study treatment.

Enrollment

230 estimated patients

Sex

All

Ages

6+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

1. Provision of signed and dated written ICF.

2. Participants completing minimum required OLE period of a parent study and judged by the Investigator to benefit from continued treatment.
3. Participants must agree to follow the contraception requirements as per their respective parent protocols from study inclusion up to 12 weeks after the last dose of study treatment.
4. Participants without childbearing potential at enrolment must agree to start appropriate contraception if childbearing potential develops during the study and up to 12 weeks after the last dose of study treatment.
5. Participants who are unable to access commercially available benralizumab and clinically indicated for continuation.

Exclusion criteria

1. Ongoing, unresolved AE requiring interruption of treatment at the end of the prior parent study (ie, when the parent study is either completed or closed) that in the Investigator's opinion would prevent restarting benralizumab.
2. Participants who are planning to use live/live-attenuated vaccines.
3. Participants who are planning to use biologic therapies, including B-cell therapies with the exception for the treatment of co-morbidities where no alternative medicine is available.
4. Participants with any medical condition (such as cancer or viral infections [hepatitis]) or psychiatric condition that, in the opinion of the Investigator, could jeopardise or would compromise the participant's ability to participate in this study as determined by the Investigator based on protocol required assessments.
5. Concurrently enrolled in any clinical study (other than a parent study).
6. Participants who discontinued the parent study prior to completing the minimum OLE or treatment period.
7. Local access to commercially available benralizumab.